# US 2024/0360200 A1 · Klk5 inhibitory peptide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0360200 A1
- Document ID: US20240360200A1
- Status: Published application
- Kind: A1
- Application number: 18/663,615
- Filed: 2024-05-14
- Published: 2024-10-31
- Earliest claimed: 2018-11-07
- Assignees: Daiichi Sankyo Company, Limited
- Applicants: Daiichi Sankyo Company, Limited
- Inventors: Daisuke Nishimiya; Hidenori Yano; Hidenori Takahashi; Shinji Yamaguchi; Shiho Ofuchi
- Web page: https://patentgrep.com/patent/US20240360200A1

## CPC

- C07K 14/81: Protease inhibitors
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 38/55: Protease inhibitors
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/811: {Serine protease (E.C. 3.4.21) inhibitors}
- C07K 14/8135: {Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12Q 1/37: involving peptidase or proteinase
- G01N 33/15: Medicinal preparations {; Physical properties thereof, e.g. dissolubility}
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 33/53: Immunoassay; Biospecific binding assay; Materials therefor
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 9/64: derived from animal tissue
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.

## Claims

### Claim 1

A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence contained in a SPINK2 mutant peptide that inhibits the protease activity of active human KLK5, wherein the peptide comprises: (i) the amino acid sequence set forth in any one of SEQ ID Nos: 6, 8, 10, 12, 14, 16, 18, and 20; or (ii) the amino acid sequence consisting of amino acids 4 to 66 of the amino acid sequence set forth in any one of SEQ ID Nos: 34, 40, and 48.

### Claim 2 (depends on 1)

The polynucleotide according to claim 1, wherein the polynucleotide encodes a conjugate comprising the SPINK2 mutant peptide and a second peptide that is not the SPINK2 mutant.

### Claim 3 (depends on 2)

The polynucleotide according to claim 2, wherein the second peptide is located on the amino terminal side of the SPINK2 mutant.

### Claim 4 (depends on 3)

The polynucleotide according to claim 3, wherein the second peptide is located on the carboxyl terminal side of the SPINK2 mutant.

### Claim 5 (depends on 4)

The polynucleotide according to claim 4, wherein the second peptide is an antibody or a fragment thereof and comprises one or more Fc regions.

### Claim 6 (depends on 5)

The polynucleotide according to claim 5, wherein each Fc region is an Fc region of human immunoglobulin, or a fragment thereof.

### Claim 7 (depends on 5)

The polynucleotide according to claim 5, wherein each Fc region is an Fc region of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD, or IgE, or a fragment thereof.

### Claim 8 (depends on 5)

The polynucleotide according to claim 5, wherein each Fc region is an Fc region of IgG1, or a fragment thereof.

### Claim 9 (depends on 8)

The polynucleotide according to claim 8, wherein each Fc region of human IgG1 comprises the amino acid sequence set forth in SEQ ID No: 87.

### Claim 10 (depends on 2)

The polynucleotide according to claim 2, wherein the encoded conjugate comprises one or more aspartic acids and/or glutamic acids added to the amino terminus thereof.

### Claim 11 (depends on 2)

The polynucleotide according to claim 2, wherein the SPINK2 mutant and the second peptide are linked to each other via a linker.

### Claim 12 (depends on 1)

A vector comprising the polynucleotide according to claim 1.

### Claim 13 (depends on 1)

A cell that comprises the polynucleotide according to claim 1 or a vector comprising the polynucleotide, or that produces the encoded SPINK2 mutant peptide.

### Claim 14 (depends on 13)

A method for producing a SPINK2 mutant peptide, comprising the steps (i) and (ii) below:
(i) culturing the cell according to claim 13; and
(ii) collecting the SPINK2 mutant peptide from the culture.

### Claim 15 (depends on 14)

A SPINK2 mutant peptide obtained by the method according to claim 14.

### Claim 16

A polynucleotide comprising a nucleotide sequence encoding the amino acid sequence contained in a conjugate, wherein the conjugate comprises:
(a) a peptide having an amino acid sequence set forth in any one of SEQ ID Nos: 34, 36, 38, 40, 42, 44, 46, 48, and 96; or
(b) a peptide having an amino acid sequence formed by the deletion of one amino acid from the amino acid sequence according to (a);
wherein the conjugate inhibits the protease activity of KLK5.

### Claim 17 (depends on 16)

A vector comprising the polynucleotide according to claim 16.

### Claim 18 (depends on 16)

A cell that comprises the polynucleotide according to claim 16 or a vector comprising the polynucleotide, or that produces the encoded conjugate.

### Claim 19 (depends on 18)

A method for producing a conjugate, comprising the steps (i) and (ii) below:
(i) culturing the cell according to claim 18; and
(ii) collecting the conjugate from the culture.

### Claim 20 (depends on 19)

A conjugate obtained by the method according to claim 19.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising the polynucleotide according to claim 1.

### Claim 22 (depends on 12)

A pharmaceutical composition comprising the vector according to claim 12.

### Claim 23 (depends on 13)

A pharmaceutical composition comprising the cell according to claim 13.

### Claim 24 (depends on 15)

A pharmaceutical composition comprising the peptide according to claim 15.

### Claim 25 (depends on 16)

A pharmaceutical composition comprising the polynucleotide according to claim 16.

### Claim 26 (depends on 17)

A pharmaceutical composition comprising the vector according to claim 17.

### Claim 27 (depends on 18)

A pharmaceutical composition comprising the cell according to claim 18.

### Claim 28 (depends on 20)

A pharmaceutical composition comprising the conjugate according to claim 20.

### Claim 29 (depends on 1)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the polynucleotide according to claim 1.

### Claim 30 (depends on 12)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the vector according to claim 12.

### Claim 31 (depends on 13)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the cell according to claim 13.

### Claim 32 (depends on 15)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the peptide according to claim 15.

### Claim 33 (depends on 16)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the polynucleotide according to claim 16.

### Claim 34 (depends on 17)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the vector according to claim 17.

### Claim 35 (depends on 18)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the cell according to claim 18.

### Claim 36 (depends on 20)

A method for treating or preventing a KLK5-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of the conjugate according to claim 20.
